Revance Therapeutics (RVNC) to Release Quarterly Earnings on Thursday

Revance Therapeutics (NASDAQ:RVNC) will issue its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.12. The company had revenue of $51.94 million during the quarter, compared to analysts’ expectations of $55.64 million. On average, analysts expect Revance Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Revance Therapeutics Stock Up 1.6 %

Shares of RVNC traded up $0.05 during trading hours on Tuesday, hitting $3.11. The company had a trading volume of 815,806 shares, compared to its average volume of 1,881,667. The firm has a market cap of $324.84 million, a P/E ratio of -0.84 and a beta of 0.98. The stock’s 50 day moving average price is $3.10 and its 200 day moving average price is $4.19. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $23.02.

Analyst Ratings Changes

RVNC has been the topic of several analyst reports. HC Wainwright decreased their price objective on Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 13th. Needham & Company LLC reduced their price target on Revance Therapeutics from $18.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Piper Sandler restated an “overweight” rating and set a $11.00 price target (down previously from $20.00) on shares of Revance Therapeutics in a report on Friday, May 10th. Mizuho reduced their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Friday, May 10th. Finally, The Goldman Sachs Group reduced their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Monday, May 13th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $11.50.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.